The Impact of IVIG Treatment on Critical Illness Polyneuropathy and/or Myopathy in Patients With MOF and SIRS/Sepsis
Status:
Terminated
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
Critical illness polyneuropathy and/or myopathy (CIPNM) is a severe complication of critical
illness. Retrospective data suggest that early application of IgM-enriched intravenous
immunoglobulin (IVIG) may prevent or mitigate CIPNM. Therefore, the primary objective was to
assess the effect of early IgM-enriched IVIG versus placebo to mitigate CIPNM in a
prospective setting.